The TAC universe grows beyond PROTACs

On the heels of success using the proteasome to degrade protein targets, a growing crop of companies are turning to autophagy to destroy a broader array of disease-driving substrates.

The TAC (therapeutic targeting chimera) space took off with modular compounds known as proteolysis targeting chimeras (PROTACs), which ubiquitinate targets and send them to the proteasome for degradation...